NCT00566280

Brief Summary

The purpose of this study is to evaluate molecular breast imaging in the workup of patients with a history of bloody nipple discharge, not reproducible in the office who have a negative clinical breast examination, and a negative diagnostic mammogram and breast ultrasound.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
14

participants targeted

Target at below P25 for not_applicable breast-cancer

Timeline
Completed

Started Oct 2006

Shorter than P25 for not_applicable breast-cancer

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2006

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

November 30, 2007

Completed
1 day until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 3, 2007

Completed
Last Updated

January 6, 2012

Status Verified

January 1, 2012

Enrollment Period

1.2 years

First QC Date

November 30, 2007

Last Update Submit

January 4, 2012

Conditions

Keywords

MBIMammogramBreast CancerBreast UltrasoundBloody Nipple DischargeMolecular Breast Imaging

Outcome Measures

Primary Outcomes (1)

  • Detection of Breast Cancer

    6 Months

Study Arms (1)

Molecular Breast Imaging

OTHER
Procedure: Molecular Breast Imaging

Interventions

A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 20 mCi of 99m Tc-sestamibi.

Also known as: MBI
Molecular Breast Imaging

Eligibility Criteria

Age25 Years - 75 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women age 25 - 75
  • Women with a negative diagnostic mammogram and ultrasound
  • Women with a history of bloody nipple discharge which can not be reproduced by the examining physician or the patient in the office

You may not qualify if:

  • Pregnant or lactating
  • Unable to understand or sign a consent form
  • Physically unable to sit upright and still for 40 minutes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mayo Clinic

Rochester, Minnesota, 55905, United States

Location

Related Publications (1)

  • Wahner-Roedler DL, Hruska CB, O'Connor MK, Phillips SW, Whaley DH, Johnson RE, Degnim AC, Boughey JC, Rhodes DJ. Molecular breast imaging for women presenting with a history of non-reproducible bloody nipple discharge and negative findings on routine imaging studies: a pilot study. J Surg Radiol. 2011 Jan 1;2(3):92-9. Epub 2010 Nov 23.

    RESULT

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Dietlind L. Wahner-Roedler, M.D.

    Mayo Clinic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

November 30, 2007

First Posted

December 3, 2007

Study Start

October 1, 2006

Primary Completion

December 1, 2007

Study Completion

December 1, 2007

Last Updated

January 6, 2012

Record last verified: 2012-01

Locations